Bolt Biotherapeutics Reports $4.31 Q1 Loss, Misses Revenue Estimates
Bolt Biotherapeutics posted a loss of $4.31 per share in Q1, missing the consensus loss estimate of $2.85 and improving from a $5.80 per-share loss a year ago. Revenues also fell short of analysts' projections, reflecting a sequential decline in top-line performance.
1. Q1 financial results
Bolt Biotherapeutics posted a loss of $4.31 per share for the quarter, well below the consensus loss estimate of $2.85 and improving from a $5.80 per-share loss in Q1 last year. Total revenue was not disclosed but was reported to have fallen short of analysts' expectations, marking a sequential decline in top-line performance.
Related News
NVDA
Nvidia Tops $91B Sales Forecast, Boosts Dividend and Buyback Program
NVDA•
SLAB
Silicon Labs SoC Powers 500,000 Wi-SUN Module Shipment for India Grid
SLAB•
INTC
Nvidia’s $91B AI Forecast, $80B Buyback Ramps Up Pressure on Intel
INTC•
META
Meta Lays Off 10% Workforce, Cancels 6,000 Hires as AI Capex Jumps
META•
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
Sources
FZ